STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1253 by analyst upside · 2026-08-13
ODTX
Odyssey Therapeutics, Inc.
Healthcare · Market Cap $1B · P/E 0x
ANALYST PRICE TARGET
+52.9%
implied upside to consensus target
Current Price $21.58
Consensus Target $33.0
Bull Target $40.0
Bear Target $29.0
Analysts Covering 3
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
2
Hold
0
Sell
0
52-Week Low $15.1
52-Week High $23.03
YTD Return +31.4%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-3.52
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $15.1
52-Week High $23.03
Current Price $21.58
Bear Target $29.0
Bull Target $40.0
● Now $21.58 ● Target $33.0
TRADING DATA
Avg Volume 309K
YTD Return +31.4%
Analyst Count 3
Consensus Buy
Upside to Target +52.9%
Last Updated 2026-08-13

ANALYST SUMMARY

Odyssey Therapeutics, Inc. (ODTX) is currently trading at $21.58 with a Wall Street consensus price target of $33.0, implying potential upside of 52.9% over the next 12 months. 3 analysts currently cover ODTX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $40.0, while the most cautious has a target of $29.0.

ODTX operates in the Healthcare sector with a market capitalisation of $1B. The stock is up 31.4% year-to-date and is currently trading near the upper end of its 52-week range of $15.1 – $23.03.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ODTX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Oppenheimer reit
Outperform → Outperform 2026-06-18 14% win rate (7 calls)
Cantor Fitzgerald ● Initiated
Overweight 2026-06-02 40% win rate (10 calls)
TD Cowen ● Initiated
Buy 2026-06-02 Building track record
Wedbush ● Initiated
Outperform 2026-06-02 Building track record
JP Morgan ● Initiated
Overweight 2026-06-02 43% win rate (7 calls)
Oppenheimer ● Initiated
Outperform 2026-06-02 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
58
out of 100
Coverage depth
11/30
Consensus clarity
20/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →